Jugendliche Patientin mit systemischem Lupus erythematodes

• Literatur

• 1 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
• 2 Mina R, Brunner HI. Pediatric lupus – are there differences in presentation, genetics, response to therapy, and damage acrcrual compared with adult lupus?. Rheum Dis Clin North Am 2010; 36: 53-80.
• 3 Ginzler EM. et al. Non-renal disease activity following mycophenolatemofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62 (01) 211-221.
• 4 Touma Z. et al. Myco phenolatemofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 2011; 38 (01) 69-78.
• 5 Dooley MA. et al. Mycophenolatemofetil versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365 (20) 1886-1895.
• 6 Houssiau FA. et al. Azathioprine versus mycophenolatemofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69 (12) 2083-2089.
• 7 Ruiz-Irastorza G. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69 (01) 20-28.
• 8 Merrill JT. et al. Efficacy and safety of Rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
• 9 Aringer M. et al. Lupus. 2012; 21 (04) 386-401.